Fixed‐dose combination therapy for the prevention of atherosclerotic cardiovascular diseases
E Bahiru, AN De Cates, MRB Farr… - Cochrane Database …, 2017 - cochranelibrary.com
Background Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death
and disability worldwide, yet ASCVD risk factor control and secondary prevention rates …
and disability worldwide, yet ASCVD risk factor control and secondary prevention rates …
Peripheral edema associated with calcium channel blockers: incidence and withdrawal rate–a meta-analysis of randomized trials
Objective Peripheral edema is considered to be a common and annoying adverse effect of
calcium channel blockers (CCBs). It has been thought to occur secondary to arteriolar …
calcium channel blockers (CCBs). It has been thought to occur secondary to arteriolar …
Value of primordial and primary prevention for cardiovascular disease: a policy statement from the American Heart Association
The process of atherosclerosis may begin in youth and continue for decades, leading to both
nonfatal and fatal cardiovascular events, including myocardial infarction, stroke, and sudden …
nonfatal and fatal cardiovascular events, including myocardial infarction, stroke, and sudden …
Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing
E Björnsson, EI Jacobsen, E Kalaitzakis - Journal of hepatology, 2012 - Elsevier
BACKGROUND & AIMS: Limited data exist on drug-induced liver injury (DILI) associated
with statins. METHODS: Reports on adverse reactions suspected to be due to statins …
with statins. METHODS: Reports on adverse reactions suspected to be due to statins …
Fixed‐dose combination therapy for the prevention of cardiovascular disease
AN de Cates, MRB Farr, N Wright… - Cochrane Database …, 2014 - cochranelibrary.com
Background Cardiovascular disease (CVD) is the leading cause of death and disability
worldwide, yet CVD risk factor control and secondary prevention rates remain low. A fixed …
worldwide, yet CVD risk factor control and secondary prevention rates remain low. A fixed …
Some aspects of Treatment of Patients having Dislipidemia on the Background of Hypertension
IA Skoryatina, SY Zavalishina, ON Makurina… - Prensa Medica …, 2017 - elibrary.ru
At present dislipidemia and hypertension are considered as leading independent risk factors
of cardio-vascular pathology. Their effective treatment leads to significant decrease of …
of cardio-vascular pathology. Their effective treatment leads to significant decrease of …
Simultaneous determination of atorvastatin, amlodipine, ramipril and benazepril in human plasma by LC‐MS/MS and its application to a human pharmacokinetic study
NR Pilli, JK Inamadugu, R Mullangi… - Biomedical …, 2011 - Wiley Online Library
A rapid, simple, sensitive and specific LC‐MS/MS method has been developed and
validated for the simultaneous estimation of atorvastatin (ATO), amlodipine (AML), ramipril …
validated for the simultaneous estimation of atorvastatin (ATO), amlodipine (AML), ramipril …
Development and validation of a liquid chromatography–tandem mass spectrometry method for simultaneous determination of amlodipine, atorvastatin and its …
Y Zhou, J Li, X He, M Jia, M Liu, H Li, Z Xiong… - … of pharmaceutical and …, 2013 - Elsevier
A sensitive, simple and rapid high-performance liquid chromatography coupled with positive
ion electrospray ionization-tandem mass spectrometry (HPLC–ESI-MS/MS) method was …
ion electrospray ionization-tandem mass spectrometry (HPLC–ESI-MS/MS) method was …
A novel programme to evaluate and communicate 10‐year risk of CHD reduces predicted risk and improves patients' modifiable risk factor profile
JS Benner, L Erhardt, M Flammer… - … journal of clinical …, 2008 - Wiley Online Library
Aims: We assessed whether a novel programme to evaluate/communicate predicted
coronary heart disease (CHD) risk could lower patients' predicted Framingham CHD risk vs …
coronary heart disease (CHD) risk could lower patients' predicted Framingham CHD risk vs …
Atorvastatin for lowering lipids
Background This represents the first update of this review, which was published in 2012.
Atorvastatin is one of the most widely prescribed drugs and the most widely prescribed statin …
Atorvastatin is one of the most widely prescribed drugs and the most widely prescribed statin …